Egle Therapeutics

Egle Therapeutics SAS is an emerging biotechnology company focused on developing first-in-class immunotherapies targeting suppressive regulatory T cells (Tregs) for oncology and autoimmune diseases. Egle Therapeutics has developed first-in-class immunotherapies targeting suppressive regulatory T cells (Tregs) for oncology and autoimmune diseases.